Dana-Farber Cancer Institute | Strategic Alliance Partners

Nancy U. Lin, MD, discusses the importance of the DESTINY-Breast12 trial of T-DXd in patients with HER2+ breast cancer with vs without brain metastases.

Dana-Farber Cancer Institute has used weighted blankets to aid in patient care.

In focus groups conducted in the US, doctors and patients expressed openness to considering environmental factors when discussing treatment options.

Cigall Kadoch, PhD, has been named as the Laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences.

Clinical trials may be inappropriately excluding some people with "Duffy-null phenotype," a trait found in people of African or Middle Eastern descent.

Marc Machaalani, MD, discusses an investigation into the distribution of ERBB2 amplifications across sex, race, and varying cancer types.

Research from Dana-Farber Cancer Institute clinicians showed that adding nivolumab to tivozanib did not improve survival for patients with advanced RCC.

Kimmie Ng, MD, MPH, discusses factors of consideration for later-line treatment decisions in patients with refractory metastatic colorectal cancer.

Breast cancer experts highlight early-phase and real-world studies of interest from the 2024 ESMO Congress.

Toni K. Choueiri, MD, discusses early findings from a phase 1/2 trial evaluating NKT2152 in previously-treated advanced clear cell renal cell carcinoma.

T-DXd shows substantial antitumor activity in brain metastases in patients with HER2-positive breast cancer in a major international clinical trial.

Kimmie Ng, MD, MPH, discusses the addition of vitamin D to standard chemotherapy plus bevacizumab in patients with untreated metastatic colorectal cancer.

Oncology experts share their key takeaways in genitourinary cancers and recent updates from the 2024 ESMO Congress.

Ann H. Partridge, MD, MPH, discusses unique challenges associated with very young patients who have ER+/node-positive breast cancer.

The SOLARIS trial results suggest that high-dose vitamin D3 cannot be recommended as a treatment for patients with untreated metastatic colon cancer.

Alicia Morgans, MD, MPH, discusses prior data and follow-up analysis of the ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Paolo Tarantino, MD, discusses advancements that may lead to more tailored treatment approaches in early-stage HER2+ breast cancer.

Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

The addition of nivolumab to tivozanib did not improve outcomes in metastatic RCC and 1.34 mg of tivozanib monotherapy may be considered as a second-line therapy.

Laurie H. Glimcher, MD, announced today that she will step down as Dana-Farber Cancer Institute President and CEO on October 1, 2024, and will assume the title of President Emerita.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

Dato-DXd did not significantly improve overall survival compared with docetaxel for patients with non–small cell lung cancer.

The study alters the existing paradigm that CDK1-Cyclin B1 is the only CDK-cyclin complex essential for all stages of mitosis.

Systematic identification of minor histocompatibility antigens informs outcomes after allogeneic stem cell transplantation.

Bradley McGregor, MD, discusses the current NCCN guideline recommendations for the treatment of patients with divergent RCC histologies.

Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.

Dr Florez discusses ways that she helps patients with lung cancer understand the importance of biomarker testing.

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

Emre Yekedüz, MD, discusses a case study shared via social media that evaluated treatment options for a patient with clear cell renal cell carcinoma.